

# The 32nd Annual Meeting of the British Society of Toxicological Pathology (BSTP)

## Pathology and toxicity of biologics and biotherapeutics

Thursday 16th & Friday 17th November 2017  
The Mere Hotel, Knutsford, Cheshire WA16 6LJ



### PROGRAMME as at 19th October 2017

Approved by the Royal Society of Biology for purposes of CPD,  
this event may be counted as 30 CPD credits

10 hours of educational activity will be recorded on Attendance Certificates

Thursday 16th November 2017	
08.45 - 09.15	Registration
09.15 - 09.30	Introduction by the Scientific Organiser
09.30 - 09.45	Technology on the pitch <i>2-minute overview from each of the exhibitors</i>
09.45 - 10.30	Safety assessment of monoclonal antibodies - challenges & opportunities to optimize our models <i>Frank Brennan, UCB, UK</i>
10.30 - 11.00	Novel delivery modalities for biologics <i>Nick Edmunds, AstraZeneca, UK</i>
11.00 - 11.30	Exhibitor Tour and Break
11.30 - 12.00	Changing treatment modalities in pharma & their scientific & regulatory impact <i>Stefan Platz, AstraZeneca, UK</i>
12.00 - 12.30	Biologics to treat CNS disease <i>Kevin Brady, UCB, UK</i>
12.30 - 13.30	Lunch
13.30 - 14.00	CAR-T cells <i>Michaela Sharpe, Cell &amp; Gene Therapy Catapult, UK</i>
14.00 - 14.30	In vitro investigation of safety-relevant immunological effects for biologics <i>Andrea Kiessling, UCB, UK</i>
14.30 - 15.30	<b>The Royal College of Pathologists: The Kettle Lecture</b> In vivo preclinical & microscopic manifestations of unexpected 'immune' related effects of biologics and biotherapeutics <i>James Raymond, Charles River Laboratories, USA</i>
15.30 - 16.00	Exhibitor Tour and Break
16.00 - 16.45	The potential impact of anti-drug antibodies on pharmacokinetics, toxicity & risk assessment of mAb-based biologics <i>Lolke de Haan, MedImmune, UK</i>
16.45 - 17.15	<b>The Royal College of Pathologists: The Cameron Lecture</b> Pathology & lesions associated with ADA & the impact on safety evaluation <i>Maurice Cary, Pathology Experts GmbH, Switzerland</i>
17.15 - 18.15	BSTP Annual General Meeting
19.00 - 19.30	Welcome Reception (The Mere Hotel)
19.30 for 20.00	Conference Dinner (The Mere Hotel)

Friday 17th November 2017	
08.30 - 09.00	<b>Registration and Exhibitors</b>
09.05 - 09.15	<b>Introduction to Day 2</b>
09.15 - 09.45	<b>Respiratory pathologies of inhaled biologics</b> <i>Ronnie Chamanza, Johnson &amp; Johnson, Belgium</i>
09.45 - 10.15	<b>An introduction to the immunity of the lung</b> <i>Catherine Betts, AstraZeneca, UK</i>
10.15 - 10.45	<b>Break</b>
10.45 - 11.45	<b>Case Presentation</b> - Thierry Flandre, Novartis, Switzerland
	<b>Case Presentation</b> - James Cartwright, AstraZeneca, UK
	<b>Case Presentation</b> - Peter Hall, UCB, UK
11.45 - 12.45	<b>Review of marketed inhaled biologics</b> <i>Marcie Wood, ToxStrategies, USA</i>
12.45 - 13.05	<b>Round Table Discussion</b> Marcie Wood, Thierry Flandre, Peter Hall & James Cartwright
13.05 - 14.00	<b>Lunch</b>
14.00 - 14.30	<b>Immunomodulation in NHP: Practical consequences – how to run studies</b> <i>Thierry Flandre, Novartis, Switzerland</i>
14.30 - 15.30	<b>Infections in NHP – how to translate to humans</b> <i>Maurice Cary, Pathology Experts GmbH, Switzerland</i>
15.30 - 16.00	<b>Break</b>
16.00 - 16.15	<b>Closing Remarks</b>
16.15	<b>Meeting Close</b> <i>Take down posters and exhibits</i>

**You are advised that the programme timings, lecture title and speakers may be subject to change without notice**